Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CART-TnMUC1 in Advanced Solid Tumors and Multiple Myeloma
NCT04025216Phase 1Terminated
- Sponsor
- Kite Pharma
- Start
- Oct 2019
- Primary completion
- Dec 2022
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CART-TnMUC1 in non-small cell lung cancer (NSCLC), ovarian cancer, fallopian tube cancer (PFTC) and 3 more (2 arms), sponsored by Kite Pharma. Primary endpoints: Dose Identification of CART-TnMUC1 up to 2 years and Objective Response Rate up to 2 years. Started Oct 2019; status: terminated.
02
Drugs
CART-TnMUC1
03
Conditions
non-small cell lung cancer (NSCLC)ovarian cancerfallopian tube cancer (PFTC)triple-negative breast cancer (TNBC)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04025216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04025216.